论文部分内容阅读
目的通过对血清、胸腔积液中癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、糖抗原50(CA50)肿瘤标志物(TM)联检的方法,探讨TM与肺癌的相关性,寻找提高肺癌诊断的阳性率及预后评估的最佳手段。方法对91例肺癌患者分别于治疗前、治疗后第6周、第6个月通过血清进行CEA、NSE、CA50单检和联检。结果肺癌患者血清中3种TM含量明显高于对照组,差异有非常显著性(P<0.01);术后残留和转移倾向者TM含量回落不显著;血清CEA+NSE+CA50联合检测阳性率分别可达91.2%,明显高于单检(P<0.01)。结论联检血清CEA+NSE+CA50可提高肺癌诊断的阳性率,对肺癌的早期诊断具有重要作用,尤其对术后疗效及转移的评估具有特异的价值。
Objective To explore the relationship between TM and lung cancer by examining the serum CEA, NSE and CA50 tumor markers (TM) in serum and pleural effusion , Looking for ways to improve the positive rate of lung cancer diagnosis and prognosis assessment. Methods Ninety-one patients with lung cancer were tested by CEA, NSE and CA50 respectively before treatment, 6 weeks and 6 months after treatment. Results The levels of three TM in the serum of patients with lung cancer were significantly higher than those in the control group (P <0.01), and the levels of TM in postoperative residual and metastatic patients did not drop significantly. The positive rates of serum CEA + NSE + CA50 Up to 91.2%, significantly higher than the single test (P <0.01). Conclusions The combined detection of serum CEA + NSE + CA50 can improve the positive rate of lung cancer diagnosis, which plays an important role in the early diagnosis of lung cancer, especially for the evaluation of postoperative efficacy and metastasis.